Acute Lymphocytic Leukemia: Learning Objectives
Medical Importance
The acute leukemias are aggressive malignancies that originate in a hematopoietic stem cell and are rapidly fatal without immediate treatment. Although acute lymphocytic leukemia (ALL) remains a devastating illness, a significant portion of patients can now be cured with intensive chemotherapy. Childhood ALL is the most common malignancy of children and approximately 80 percent of patients will be cured. Unfortunately, only 30-40 percent of adults with ALL will be cured. The difference in outcome can be attributed in large part to the higher frequency of adverse genetic abnormalities in the leukemic cells of adults with ALL. Early recognition and diagnosis of ALL, and an appreciation of its complications, will lead to timely supportive interventions and the potential for curative therapy.
Objectives
- Identify the age and gender distribution of patients with ALL.
- Name common symptoms/signs and common laboratory findings in a patient presenting with ALL.
- Briefly describe two tests that can be used to distinguish leukemic blast cells of ALL from leukemic blast cells of AML.
- Therapy of ALL commonly consists of an induction phase, post-remission therapy (consolidation and maintenance therapy), and central nervous system prophylaxis. Describe the goals of each of these three elements of therapy.
- Describe one complication that leads to mortality in ALL.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission